BRCA2 and neoplasm: In summary, these results indicate a strong anti-tumor effect of the everolimus+olaparib combination in the BRCA2 basal-like breast cancer PDX HBCx-17, with evidence of increased DNA damage in all treatment arms and inhibition of key component of the homologous recombination pathway.